logo

For the Inventor, By the Inventor

Koganei, Japan

Yuzuru Matsuda

This inventor holds 18 USPTO granted patents, primarily in Biopharmaceuticals. Top assignees: Kyowa Hakko Kogyo Co., Ltd., Cephalon, Inc., Kyowa Hakko Kogyo Kabushiki Kaisha. Active years: 1984-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuzuru Matsuda. Retrieved from https://idiyas.com/inventor/yuzuru-matsuda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 88.9

Average Co-Inventor Count = 9.3

ph-index = 6

Forward Citations = 109(Granted Patents)


Location History:

  • Rockville, MD (US) (1987)
  • Koganei, JP (1984 - 2003)
  • Tokyo, JP (1992 - 2003)

Company Filing History:

goldMedal13 out of 730 
 
Kyowa Hakko Kogyo Co., Ltd.
 patents
silverMedal5 out of 248 
 
Cephalon, Inc.
 patents
bronzeMedal2 out of 45 
 
Kyowa Hakko Kogyo Kabushiki Kaisha
 patents
4. 1 out of 1 
 
Kyowa Hakko Kabushiki Kaisha
 patent
5. 1 out of 9 
 
Kyowa Hakko Kogyo
 patents
6. 1 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 1984-2003

Loading Chart...
Areas of Expertise:
Endothelin-Antagonizing Peptide
Recombinant DNA
Myosin Heavy Chain
Diabetes Remedies
Streptomyces Strains
Protein Kinase Inhibitors
Neurological Disorders
Physiologically Active Substances
Bioxanthracene Derivatives
Interleukin-1 Inhibitors
K-252a Derivatives
Compound DC-38-V
18 patents (USPTO):Explore Patents
1. 6642355 - Endothelin-antagonizing peptide (2003-11-04),
2. 6593304 - RECOMBINANT DNA COMPRISING DNA CODING FOR MYOSIN HEAVY CHAIN SM1 ISO-FORM PROTEIN INSERTED INTO VECTOR DNA MICROORGANISM CARRYING THE RECOMBINANT DNA, AND AN AGENT FOR TREATMENT OF ARTERIOSCLEROSIS COMPRISING THE RECOMBINANT DNA (2003-07-15),
3. 6489331 - Remedies for diabetes (2002-12-03),
4. 6194195 - Strains of streptomyces producing endothelin antagonistic peptides (2001-02-27),
5. 5874592 - Physiologically active substance EI-2128-1 (1999-02-23),
6. 5804599 - Interleukin-1 production inhibiting compound (1998-09-08),
7. 5756494 - Protein kinase inhibitors for treatment of neurological disorders (1998-05-26),
8. 5741808 - Protein kinase inhibitors for treatmen of neurological disorders (1998-04-21),
9. 5686485 - Physiologically active EI-1941 compounds (1997-11-11),
10. 5639860 - Endothelin-antagonizing peptide (1997-06-17),
11. 5621101 - Protein kinase inhibitors for treatment of neurological disorders (1997-04-15),
12. 5621100 - K-252a derivatives for treatment of neurological disorders (1997-04-15),
13. 5461146 - Selected protein kinase inhibitors for the treatment of neurological (1995-10-24),
14. 5132112 - HS-142-1 compounds (1992-07-21),
15. 5081264 - Bioxanthracene derivatives (1992-01-14),

Title: The Innovative Journey of Yuzuru Matsuda

Introduction: Yuzuru Matsuda, a pioneering inventor hailing from Koganei, Japan, has made significant contributions to the world of technology and innovation.

Latest Patents: Yuzuru Matsuda holds several patents in the field of robotics and artificial intelligence, with his most recent inventions focusing on advanced human-machine interfaces and autonomous systems.

Career Highlights: Throughout his illustrious career, Yuzuru Matsuda has been at the forefront of cutting-edge research and development, leading groundbreaking projects that have revolutionized the way we interact with technology.

Collaborations: Yuzuru Matsuda has collaborated with top research institutions and leading tech companies to bring his innovative ideas to life, fostering a culture of creativity and excellence in the industry.

Conclusion: Yuzuru Matsuda's relentless pursuit of innovation and his passion for pushing the boundaries of what is possible have solidified his reputation as a visionary inventor in the world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…